Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Translational Research Program (primary immunodeficiency | worldwide)

Jeffrey Modell Foundation

Purpose

To support innovative and novel investigations in Primary Immunodeficiency focusing on translational research leading to meaningful clinical application.
To advance the growing knowledge of genotype-phenotype correlations and gain a better understanding of the underlying mechanisms of immune function and dysfunction.
To support research that will lead to advancement in clinical recognition, diagnostic tools, and innovative therapies that will impact overall health outcomes and improve the quality of life of those affected by Primary Immunodeficiency.

To date, over 500 specific genetic defects have been identified, which have not only helped advance new therapies, but have also been instrumental in advancing our understanding of immunology. It is estimated that as many as 10 million people, if not more, are living with Primary Immunodeficiency worldwide. As such, it is crucial to support research that will bridge basic scientific discoveries to the development of clinical applications that will impact overall health outcomes. Advancing research that enhances our understanding of the immune system represents one of the single greatest strategies that biomedical science has to offer to identify new therapies and will greatly benefit those living with diagnosed Primary Immunodeficiencies as well as the millions of people that remain undiagnosed

Specialties

Immunology

Others

Eligibility Requirements

Grants with the following focus will be strongly considered for awards:

Novel Primary Immunodeficiency defects
Innovative approaches to early diagnosis - Novel therapeutic strategies
Translational impact on patient health (i.e., how a patient will benefit)
Reach of the proposed project (i.e., how many patients might benefit)
Projects that currently do not have funding and would be otherwise difficult to advance without this award

The Jeffrey Modell Foundation encourages all international and U.S. investigators with the appropriate knowledge and research skill level to apply for this grant. Applications submitted by investigators with vast expertise in Primary Immunodeficiency, as well as young investigators with robust scientific merit will be considered. JMF encourages investigators who are not currently receiving funding from the National Institutes of Health to apply. Only one active grant per investigator is permitted at a time. See the list of historic award recipients and proposal titles here.

Sponsor Details

Sponsor Institute/Organizations: Jeffrey Modell Foundation

Sponsor Type:

Address: 780 Third Avenue, 47th Floor New York, NY 10017 Fax: 212-764-4180

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity